

online from January 2009



ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

- ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

● Selection of Recent Articles

Differentially Regulated Genes in MEN1 Transfected BON Cells Using RT-differential Display, and Oligonucleotide Microarrays. J.R. LOPEZ-EGIDO, Y. WANG, M. GRÖNBERG, P. GRIMFJÄRD, S. WANG, P. STÅLBERG, B. SKOGSEID (*Uppsala, Sweden*)

Bortezomib Therapeutic Effect Is Associated with Expression of FGFR3 in Multiple Myeloma Cells. M. GUAN, L. ZHU, G. SOMLO, A. HUGHES, B. ZHOU, Y. YEN (*Duarte, CA, USA; Zhejiang, China*)

Utilization of a Right-handed Coiled-coil Protein from Archaeobacteria *Staphylothermus marinus* as a Carrier for Cisplatin. M. ERIKSSON, S. HASSAN, R. LARSSON, S. LINDER, T. RAMQVIST, H. LÖVBORG, T. VIKINGE, E. FIGGEMEIER, J. MÜLLER, J. STETEFELD, T. DALIANIS, S. ÖZBEK (*Stockholm; Uppsala; Linköping, Sweden; Basel, Switzerland; Winnipeg, Manitoba, Canada; Heidelberg, Germany*)

An Orally Active Small Molecule TGF- β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer. M.P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M.E. MERCADO-PIMENTEL, R.B. RUNYAN, D.G. BESSELSSEN, X. ZHANG, H.-K. CHEUNG, W.-C. LEE, L.E. LING, E.T. AKPORIAYE (*Tucson, AZ; Portland, OR; Cambridge, MA, USA*)

Overexpression of Adenovirus-mediated p27kip1 Lacking the Jab1-Binding Region Enhanced Cytotoxicity and Inhibited Xenografted Human Cholangiocarcinoma Growth. S. SHIRASO, Y. KATAYOSE, K. YAMAMOTO, M. MIZUMA, S. YABUUCHI, A. ODA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. HAYASHI, H. OHTSUKA, F. MOTOI, S. EGAWA, J. KATO, M. UNNO (*Sendai; Nara, Japan*)

Analysis of Factors Influencing Dysphagia Severity Following Treatment of Head and Neck Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, U. KARLSSON, P.D. NGUYEN, H.W.C. WARD, P. VOS, H.J. SMITH, S. HUANG, L.M. NGUYEN, C. LEMANSKI, A. LUDIN, S. SALLAH (*Tucson, AZ; Dallas, TX; Greenville, NC; Ann Arbor, MI; Cleveland, OH, USA; Montpellier, France; Athens, Greece*)

The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44+CD24-/low Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANNO (*Fukuoka, Japan*)

A Role for the Substance P/NK-1 Receptor Complex in Cell proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLE, D. TOSTES, F. ESTABAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (*Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain*)

Comparison of Cell Death-inducing Effect of Novel Taxane SB-T-1216 and Paclitaxel in Breast Cancer Cells. J. KOVÁ, M. EHRLIHOVÁ, B. ŠMEJKALOVÁ, I. ZANARDI, I. OJIMA (*Prague, Czech Republic; Stony Brook, NY, USA*)

Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous-cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (*Lyon, France*)

Vessel Dilator and Kaliuretic Peptide Inhibit Ras in Human Prostate Cancer Cells. Y. SUN, E.J. EICHELBAUM, W.P. SKELTON IV, A. LENZ, H. WANG, D.L. VESELY (*Tampa, FL, USA*)

Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling. K. KATAYAMA, K. SHIBATA, J. MITSUHASHI, K. NOGUCHI, Y. SUGIMOTO (*Tokyo, Japan*)

Levonorgestrel, Medroxyprogesterone and Progesterone Cause a Concentration-dependent Reduction in Endometrial Cancer (Ishikawa) Cell Density, and High Concentrations of Progesterone and Mifepristone Act in Synergy. B.T. MOE, A.B. VEREIDE, A. ØRBO, R. JÆGER, G. SAGER (*Tromsø, Norway*)

- **Editorial Office:** Manuscripts and correspondence should be addressed to: Dr. John G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.
Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

- For more information about Anticancer Research and IIAR, please visit the IIAR website: www.iiar-anticancer.org

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org (mail to: journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO and CANCER GENOMICS & PROTEOMICS
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

online from January 2009
 HighWire Press®
 STANFORD UNIVERSITY

www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, *^oDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

Single-step Therapy – Feasibility and Safety of Simultaneous Transarterial Chemoembolization and Radiofrequency Ablation for Hepatic Malignancies. C. GADALETA, A. CATINO, G. RANIERI, V. FAZIO, G. GADALETA-CALDAROLA, A. CRAMAROSSA, F. ARMENISE, E. CANNIELLO, G. VINCIARELLI, G. LARICCHIA, V. MATTIOLI (<i>Bari, Italy</i>)	813
Bolus 5-Fluorouracil as an Alternative Modality to Infusion 5-Fluorouracil in a Patient with Rectal Cancer and Capecitabine-induced Cardiotoxicity. W. SHAIB, V. LEE, M.W. SAIF (<i>New Haven, CT, USA</i>)	821
Circulating Cytokine Levels in Prostate Cancer Patients Undergoing Radiation Therapy: Influence of Neoadjuvant Total Androgen Suppression. R.M. JOHNKE, J.M. EDWARDS, M.J. EVANS, G.N. NANGAMI, N.T.G. BAKKEN, J.M. KILBURN, T.-K. LEE, R.R. ALLISON, U.L. KARLSSON, H.H. ARASTU (<i>Greenville, NC, USA</i>).....	827
Paraneoplastic Cerebellar Degeneration in a Patient with Pseudomyxoma Peritonei and Breast Cancer: Case Report and Literature Review. A. ARDAVANIS, D. SYKOUTRI, P. KOUNTOURAKIS, D. DOUFEXIS, D. KORKOLIS, H. TZERBINI, I. SKARLATOS, E. MOSA, G. RIGATOS (<i>Athens, Greece</i>)	835
Detection of Herpes Simplex Virus in First Trimester Pregnancy Loss Using Molecular Techniques. N.C. KAPRANOS, D.C. KOTRONIAS (<i>Athens, Greece</i>).....	839
The Role of Postoperative Radiotherapy in the Management of Patients with Thymic Tumors – A Retrospective Study. V. VASSILIOU, A. TSAMANDAS, N. KATODRITIS, N. CHAROULIS, A. KOUKOUMA, D. ANDREOPOULOS, S. SALAKOU, V. ZOLOTA, P. PAPATHANASSOPOULOS, G. CHRISTODOULIDES, D. DOUGENIS, D. KARDAMAKIS (<i>Patras, Greece; Nicosia, Cyprus</i>).....	843
Evaluation of Early Dynamic Splinting <i>versus</i> Static Splinting for Patients with Transposition of the Extensor Carpi Radialis Longus to the Extensor Pollicis Longus. I. JUSTAN, G. BISTONI, Z. DVORAK, P. HYZA, I. STUPKA, J. VESELY (<i>Brno, Czech Republic; Rome, Italy</i>)	853
Changes in the Mechanical Properties of Human Quadriceps Muscle after Eccentric Exercise. A. PHILIPPOU, M. MARIDAKI, G. BOGDANIS, A. HALAPAS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	859
Pulmonary Function Testing in Women with Breast Cancer Treated with Radiotherapy and Chemotherapy. D. SPYROPOULOU, M. LEOTSINIDIS, M. TSAMITA, K. SPIROPOULOS, D. KARDAMAKIS (<i>Patras, Greece</i>).....	867
Custom-made Reduction Mammoplasty. M. TARALLO, C. MONARCA, M.I. RIZZO, E. CIGNA, N. SCUDERI (<i>Rome, Italy</i>).....	873
Erratum.....	877

* Reviews (pages 779, 797)

Expression of Breast Cancer Resistance Protein (BCRP-1) in Canine Mammary Adenocarcinomas and Adenomas. M. NOWAK, J.A. MADEJ, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>).....	705
Modelling of Tumour–Host Coexistence <i>In Vitro</i> in the Presence of Serine Protease Inhibitors. H. ENGI, N. GYÉMÁNT, M. OHKOSHI, L. AMARAL, J. MOLNÁR (<i>Szeged; Budapest, Hungary; Abiko-shi, Japan; Lisbon, Portugal</i>)	711
The Mitochondria-targeted Nitroxide JP4-039 Augments Potentially Lethal Irradiation Damage Repair. M.S. RAJAGOPALAN, K. GUPTA, M.W. EPPERLY, D. FRANICOLA, X. ZHANG, H. WANG, H. ZHAO, V.A. TYURIN, J.G. PIERCE, V.E. KAGAN, P. WIPF, A.J. KANAI, J.S. GREENBERGER (<i>Pittsburgh, PA, USA</i>).....	717
Endothelial Nitric Oxide Synthase Is Up-regulated in the Umbilical Cord in Pregnancies Complicated with Intrauterine Growth Retardation. Z. HRACSKO, E. HERMESZ, A. FERENCZ, H. ORVOS, Z. NOVAK, A. PAL, I.S. VARGA (<i>Szeged, Hungary</i>).....	727
Effect of Melatonin on Melanoma Cells Subjected to UVA and UVB Radiation in <i>In Vitro</i> Studies. I. IZYKOWSKA, E. GEBAROWSKA, M. CEGIELSKI, M. PODHORSKA-OKOLOW, A. PIOTROWSKA, M. ZABEL, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>).....	733
Effect of Melatonin on Human Keratinocytes and Fibroblasts Subjected to UVA and UVB Radiation <i>In Vitro</i> . I. IZYKOWSKA, M. CEGIELSKI, E. GEBAROWSKA, M. PODHORSKA-OKOLOW, A. PIOTROWSKA, M. ZABEL, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>).....	739
Hepatoprotection of Chlorella against Carbon Tetrachloride-induced Oxidative Damage in Rats. H.-Y. PENG, Y.-C. CHU, S.-J. CHEN, S.-T. CHOU (<i>Taichung; Changhua, Taiwan, ROC</i>).....	747
<i>Gandoderma lucidum</i> Extract Promotes Immune Responses in Normal BALB/c Mice <i>In Vivo</i> . Y.-H. CHANG, J.-S. YANG, J.-L. YANG, C.-L. WU, S.-J. CHANG, K.-W. LU, C.-L. KUO, T.-C. HSIA, J.-G. CHUNG (<i>Taichung, Taiwan, ROC</i>).....	755
Effects of <i>Agaricus blazei</i> Murill Extract on Immune Responses in Normal BALB/c Mice. N.-Y. TANG, J.-S. YANG, J.-P. LIN, T.-C. HSIA, M.-J. FAN, J.-J. LIN, S.-W. WENG, Y.-S. MA, H.-F. LU, J.-J. SHEN, J.-G. LIN, J.-G. CHUNG (<i>Taichung; Taipei; Taoyuan, Taiwan, ROC</i>).....	761
Breast Cancer and Cyclin D1 Gene Polymorphism in Turkish Women. İ. YAYLIM-ERALTAN, A. ERGEN, U. GÖRMÜŞ, S. ARIKAN, S. KÜÇÜCÜK, O. ŞAHİN, N. YİĞİT, Y. YILDIZ, T. İSBİR (<i>Istanbul, Turkey</i>).....	767
Effect of <i>Sasa senanensis</i> Rehder Extract on NO and PGE ₂ Production by Activated Mouse Macrophage-like RAW264.7 Cells. L. ZHOU, K. HASHIMOTO, K. SATOH, Y. YOKOTE, M. KITAJIMA, T. OIZUMI, H. OIZUMI, H. SAKAGAMI (<i>Saitama; Tokyo; Kanagawa, Japan</i>)	773
* Review: Muscle Regeneration: Cellular and Molecular Events. M. KARALAKI, S. FILI, A. PHILIPPOU, M. KOUTSILIERIS (<i>Athens, Greece</i>).....	779
<i>Clinical Studies</i>	
* Review: Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors. A. GLUBA, M. BANACH, D.P. MIKHAILIDIS, J. RYSZ (<i>Lodz, Poland; London, UK</i>).....	797